Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New ultrasound technique aims to spot cancer without radiation

NCT ID NCT04136912

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new 3D ultrasound technique called acoustic angiography to improve imaging of breast and thyroid tumors. Researchers planned to enroll 45 people, including healthy volunteers and patients scheduled for biopsy. The study was stopped early due to funding problems, so only limited data were collected.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
perflutren (Definity)
What this could lead to
If successful, this imaging method could help doctors see tiny blood vessels in tumors more clearly, potentially improving cancer detection without radiation.
What could go wrong
The study was terminated early due to lack of funding, so results are very limited. It was a small, early-phase trial, and the technique may not prove better than standard ultrasound.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

27 people

The number who actually took part.

Started

May 2022

Finished

Aug 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Healthy Volunteers Inclusion Criteria * Able to provide informed consent * Negative urine pregnancy test in women of child-bearing potential Exclusion Criteria * Institutionalized subject (prisoner or nursing home patient) * Critically ill or medically unstable and whose critical course during the observation period would be unpredictable (e.g., chronic obstructive pulmonary disease (COPD) * Known hypersensitivity to perflutren lipid (Definity®) * Active cardiac disease including any of the following: * Severe congestive heart failure * Unstable angina. * Severe arrhythmia * Myocardial infarction within 14 days prior to the date of proposed Definity® administration. * Pulmonary hypertension * Cardiac shunts Breast Imaging Patients Inclusion Criteria * Women * Patient had a diagnostic breast ultrasound study performed at UNC * Scheduled for a core needle or surgical breast biopsy of at least one breast lesion that is 2 cm or less in size and 3 cm in depth from the skin surface * Able to provide informed consent * Negative urine pregnancy test in women of child-bearing potential * BIRADS score of 4 or 5. Exclusion Criteria * Male * Institutionalized subject (prisoner or nursing home patient) * Critically ill or medically unstable and whose critical course during the observation period would be unpredictable (e.g., chronic obstructive pulmonary disease (COPD) * Sonographically visible breast lesion larger than 2cm or greater than 3cm in depth from the skin surface * Known hypersensitivity to perflutren lipid (Definity®) * Active cardiac disease including any of the following: * Severe congestive heart failure * Unstable angina. * Severe arrhythmia * Myocardial infarction within 14 days prior to the date of proposed Definity® administration. * Pulmonary hypertension * Cardiac shunts Thyroid Imaging Patients Inclusion Criteria * Patient had a diagnostic thyroid ultrasound study performed at UNC * TIRADS risk score of 4c or 5 * Scheduled for a core needle or surgical thyroid biopsy, fine needle aspiration, or thyroidectomy of at least one sonographically visible thyroid lesion that is 3 cm in depth from the skin surface * Able to provide informed consent * Negative urine pregnancy test in women of child-bearing potential Exclusion Criteria * Institutionalized subject (prisoner or nursing home patient) * Critically ill or medically unstable and whose critical course during the observation period would be unpredictable (e.g., chronic obstructive pulmonary disease (COPD) * Known hypersensitivity to perflutren lipid (Definity®) * Active cardiac disease including any of the following: * Severe congestive heart failure * Unstable angina. * Severe arrhythmia * Myocardial infarction within 14 days prior to the date of proposed Definity® administration. * Pulmonary hypertension * Cardiac shunts

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Univeristy of North Carolina Chapel Hill

    Chapel Hill, North Carolina, 27599, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.